Aspiring breakthrough therapy sponsors likely will have to infer the necessary bar to gain a designation for the time being, until FDA gains its own handle on it.
Center for Drug Evaluation and Research Director Janet Woodcock said FDA is not writing a scientific guidance on the threshold for breakthrough therapy designation now, but may be in a position to do so after more